Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma

Publication Date:
2018-05-16
Publisher:
The American Association for Cancer Research (AACR)
Print ISSN:
1078-0432
Electronic ISSN:
1557-3265
Topics:
Medicine
Published by:
http://www.aacr.org/
_version_ 1839208051011223552
autor Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
beschreibung Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ( 90 YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m 2 ) during mobilization of stem cells, followed by 1,000 mg/m 2 on days +1 and +8 after ASCT with R-BEAM or 90 YIT-R-BEAM ( 90 YIT dose of 0.4 mCi/kg) conditioning. Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving 90 YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for 90 YIT-R-BEAM ( P = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( P = 0.65). In patients with de novo DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( P = 0.52) and DFS rates ( P = 0.64), irrespective of their time of relapse (〈1 vs. 〉1 year) after initial induction chemotherapy ( P = 0.97). Conclusions: Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of 90 YIT does not confer a further survival benefit. Clin Cancer Res; 24(10); 2304–11. ©2018 AACR .
citation_standardnr 6258909
datenlieferant ipn_articles
feed_id 9363
feed_publisher The American Association for Cancer Research (AACR)
feed_publisher_url http://www.aacr.org/
insertion_date 2018-05-16
journaleissn 1557-3265
journalissn 1078-0432
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher The American Association for Cancer Research (AACR)
quelle Clinical Cancer Research
relation http://clincancerres.aacrjournals.org/cgi/content/short/24/10/2304?rss=1
search_space articles
shingle_author_1 Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
shingle_author_2 Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
shingle_author_3 Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
shingle_author_4 Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
shingle_catch_all_1 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ( 90 YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m 2 ) during mobilization of stem cells, followed by 1,000 mg/m 2 on days +1 and +8 after ASCT with R-BEAM or 90 YIT-R-BEAM ( 90 YIT dose of 0.4 mCi/kg) conditioning. Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving 90 YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for 90 YIT-R-BEAM ( P = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( P = 0.65). In patients with de novo DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( P = 0.52) and DFS rates ( P = 0.64), irrespective of their time of relapse (<1 vs. >1 year) after initial induction chemotherapy ( P = 0.97). Conclusions: Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of 90 YIT does not confer a further survival benefit. Clin Cancer Res; 24(10); 2304–11. ©2018 AACR .
Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_2 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ( 90 YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m 2 ) during mobilization of stem cells, followed by 1,000 mg/m 2 on days +1 and +8 after ASCT with R-BEAM or 90 YIT-R-BEAM ( 90 YIT dose of 0.4 mCi/kg) conditioning. Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving 90 YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for 90 YIT-R-BEAM ( P = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( P = 0.65). In patients with de novo DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( P = 0.52) and DFS rates ( P = 0.64), irrespective of their time of relapse (<1 vs. >1 year) after initial induction chemotherapy ( P = 0.97). Conclusions: Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of 90 YIT does not confer a further survival benefit. Clin Cancer Res; 24(10); 2304–11. ©2018 AACR .
Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_3 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ( 90 YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m 2 ) during mobilization of stem cells, followed by 1,000 mg/m 2 on days +1 and +8 after ASCT with R-BEAM or 90 YIT-R-BEAM ( 90 YIT dose of 0.4 mCi/kg) conditioning. Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving 90 YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for 90 YIT-R-BEAM ( P = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( P = 0.65). In patients with de novo DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( P = 0.52) and DFS rates ( P = 0.64), irrespective of their time of relapse (<1 vs. >1 year) after initial induction chemotherapy ( P = 0.97). Conclusions: Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of 90 YIT does not confer a further survival benefit. Clin Cancer Res; 24(10); 2304–11. ©2018 AACR .
Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_4 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ( 90 YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m 2 ) during mobilization of stem cells, followed by 1,000 mg/m 2 on days +1 and +8 after ASCT with R-BEAM or 90 YIT-R-BEAM ( 90 YIT dose of 0.4 mCi/kg) conditioning. Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving 90 YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for 90 YIT-R-BEAM ( P = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( P = 0.65). In patients with de novo DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( P = 0.52) and DFS rates ( P = 0.64), irrespective of their time of relapse (<1 vs. >1 year) after initial induction chemotherapy ( P = 0.97). Conclusions: Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of 90 YIT does not confer a further survival benefit. Clin Cancer Res; 24(10); 2304–11. ©2018 AACR .
Chahoud, J., Sui, D., Erwin, W. D., Gulbis, A. M., Korbling, M., Zhang, M., Ahmed, S., Alatrash, G., Anderlini, P., Ciurea, S. O., Oran, B., Fayad, L. E., Bassett, R. L., Jabbour, E. J., Medeiros, L. J., Macapinlac, H. A., Young, K. H., Khouri, I. F.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_title_1 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
shingle_title_2 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
shingle_title_3 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
shingle_title_4 Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
timestamp 2025-07-31T23:44:40.606Z
titel Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
titel_suche Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
topic WW-YZ
uid ipn_articles_6258909